Disease severity-related alterations of cardiac microRNAs in experimental pulmonary hypertension

Area of Science:

• Cardiovascular Research
• Molecular Biology
• Pulmonary Hypertension

Background:

• Right ventricular (RV) failure is a major cause of mortality in pulmonary arterial hypertension (PAH).
• The role of specific microRNAs in the development of RV dysfunction in PAH is not fully understood.
• Heart-specific microRNAs (myomiRs) and miR-214 are investigated for their potential involvement.

Purpose of the Study:

• To investigate the role of myomiRs (miR-1, miR-133a, miR-208, miR-499) and miR-214 in the right ventricle during the development of pulmonary arterial hypertension (PAH).
• To correlate microRNA expression levels with the severity of RV hypertrophy and disease progression in a rat model of PAH.

Main Methods:

• A monocrotaline (MCT)-induced rat model was used to mimic pulmonary arterial hypertension (PAH).
• Rats were divided into control, MCT (4 weeks), and premature terminal MCT (ptMCT) groups.
• Quantitative real-time PCR (RT-qPCR) was employed to determine the expression of candidate microRNAs and myocardial damage genes.

Main Results:

• MCT-induced PAH rats exhibited reduced blood oxygen saturation, breathing difficulties, RV enlargement, and elevated myocardial damage markers.
• MyomiRs were significantly decreased, while miR-214 expression was increased specifically in the ptMCT group, indicating disease severity.
• MyomiR expression negatively correlated with RV hypertrophy (Fulton index), whereas miR-214 showed a positive correlation.

Conclusions:

• The expression patterns of specific microRNAs (myomiRs and miR-214) reflect the severity of pulmonary arterial hypertension (PAH) and right ventricular dysfunction.
• These microRNAs and their associated pathways represent potential therapeutic targets for managing PAH.